They won't raise after efficacy unless there is a huge surprise from cohort two. Investors will have to take a chance and be rewarded if there is success. You don't raise money like this on news.... You get retail to pay up and take the risk. It's normal business sense. Nearly every book I've ever been involved in is done by raising before results.
